



28 September 2015

ASX ANNOUNCEMENT

MVP receives AUD \$10million upfront payment

Medical Developments International Limited (ASX: MVP) announces that it has received the first of its payments from Mundipharma circa AUD\$10million, in relation to the recently signed License, Development and Commercialisation Agreement for Pentrox in Europe.

MVP CEO, Mr. John Sharman said “MVP is debt free and expects to generate strong cash flow from operations this financial year. The Board will no doubt consider its capital management options as part of half year reporting.”

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 3 9547 1888



About Pentrox

'Penthrox' is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. 'Penthrox' has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in 'Penthrox' being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting minor trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.